| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 349 | 2019 |
| Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis B Dhakal, A Szabo, S Chhabra, M Hamadani, A D’Souza, SZ Usmani, ... JAMA oncology 4 (3), 343-350, 2018 | 170 | 2018 |
| Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... Journal of Clinical Oncology 40 (25), 2901-2912, 2022 | 161 | 2022 |
| IVIg for treatment of severe refractory heparin-induced thrombocytopenia A Padmanabhan, CG Jones, SM Pechauer, BR Curtis, DW Bougie, ... Chest 152 (3), 478-485, 2017 | 131 | 2017 |
| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England journal of medicine 389 (4), 335-347, 2023 | 126 | 2023 |
| Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy B Dhakal, S Abedin, T Fenske, S Chhabra, N Ledeboer, P Hari, ... Blood, The Journal of the American Society of Hematology 138 (14), 1278-1281, 2021 | 114 | 2021 |
| Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study B Dhakal, LB Kreuziger, L Rein, A Kleman, R Fraser, RH Aster, P Hari, ... The Lancet Haematology 5 (5), e220-e231, 2018 | 100 | 2018 |
| Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease … LJ Costa, S Chhabra, KN Godby, E Medvedova, RF Cornell, AC Hall, ... Blood 134, 860, 2019 | 93 | 2019 |
| Allogeneic stem cell transplantation for multiple myeloma: is there a future? B Dhakal, DH Vesole, PN Hari Bone marrow transplantation 51 (4), 492-500, 2016 | 84 | 2016 |
| Effect of laser shock peening on mechanical and microstructural aspects of 6061-T6 aluminum alloy B Dhakal, S Swaroop Journal of materials processing technology 282, 116640, 2020 | 78 | 2020 |
| Laser shock peening as post welding treatment technique B Dhakal, S Swaroop Journal of Manufacturing Processes 32, 721-733, 2018 | 77 | 2018 |
| Marizomib for central nervous system‐multiple myeloma A Badros, Z Singh, B Dhakal, Y Kwok, A MacLaren, P Richardson, ... British Journal of Haematology 177 (2), 221-225, 2017 | 64 | 2017 |
| Novel biomarkers in multiple myeloma A Levin, P Hari, B Dhakal Translational Research 201, 49-59, 2018 | 45 | 2018 |
| The evolving role of translocation t (11; 14) in the biology, prognosis, and management of multiple myeloma A Paner, P Patel, B Dhakal Blood Reviews 41, 100643, 2020 | 41 | 2020 |
| Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial JM Knight, JD Rizzo, P Hari, MC Pasquini, KE Giles, A D’Souza, ... Blood Advances 4 (3), 467-476, 2020 | 41 | 2020 |
| Peripheral blood grafts for T cell–replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome RV Raj, M Hamadani, A Szabo, MC Pasquini, NN Shah, WR Drobyski, ... Biology of Blood and Marrow Transplantation 24 (8), 1664-1670, 2018 | 40 | 2018 |
| Multiple myeloma and COVID-19 B Dhakal, A D’Souza, S Chhabra, P Hari Leukemia 34 (7), 1961-1963, 2020 | 39 | 2020 |
| Morbidities of lung cancer surgery in obese patients B Dhakal, D Eastwood, S Sukumaran, G Hassler, W Tisol, M Gasparri, ... The Journal of thoracic and cardiovascular surgery 146 (2), 379-384, 2013 | 39 | 2013 |
| Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients MB Abid, M Rubin, N Ledeboer, A Szabo, W Longo, M Mohan, NN Shah, ... Cancer Cell 40 (4), 340-342, 2022 | 38 | 2022 |
| Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial A D'Souza, A Szabo, KE Flynn, B Dhakal, S Chhabra, MC Pasquini, ... EClinicalMedicine 23, 2020 | 34 | 2020 |
